Jonathan Sisson

Jon is a pharmaceutical physician with extensive knowledge of medicines development  and regulation across the whole product lifecycle.

Since joining tranScrip in January 2022, Jon has led multiple projects,  advised on all phases of clinical development, regulatory strategy and on multiple types of UK/EU/US regulatory application.

Before moving to tranScrip, Jon was a medical assessor at the UK Medicines and Healthcare Products Regulatory Agency (MHRA) for 22 years. Initially Jon worked in the post-licensing division across all therapeutic areas, with a focus on license variations, safety reviews and advertising issues. After 10 years in post-licensing, he moved to the licensing division, to assess new license applications (new chemical entities and generics) and provide national scientific advice to companies. This mainly covered products for cardiovascular conditions and diabetes, but Jon gained cumulative experience in a wider range of therapy areas, particularly when serving as a UK representative on the Committee for Medicinal Products for Human Use (CHMP) Scientific Advice Working Party.

Previously, following clinical training in internal medicine, Jon worked in the Hoechst and GlaxoWellcome clinical pharmacology units, including as Principal Investigator in first-in-man studies.

Jon has a particular interest in clinical pharmacology and pharmacokinetics, bioequivalence studies and structured risk: benefit assessment. He is a fellow of the UK Faculty of Pharmaceutical Medicine, and serves on their Board of Examiners for the Certificate and Diploma in Pharmaceutical Medicine.